Xinlan Liu

机构：Yunnan Agricultural University, Mianyang Central Hospital, Ningxia Hui Autonomous Region Peoples Hospital, Sichuan Mianyang 404 Hospital, Affiliated Hospital of North Sichuan Medical College, Ningxia Medical University, Ningxia Medical University General Hospital, National Center for Infectious Diseases, The Fourth People's Hospital of Ningxia Hui Autonomous Region, First Affiliated Hospital Zhejiang University, Zhejiang University, Hunan Institute of Technology · ORCID：0009-0004-6798-7628

发表论文 79 篇 · 总被引 965 次 · h-index 14

代表论文

• Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 124)
• A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma (2024 · European Journal of Cancer · 被引 30)
• Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial (2024 · Journal of Clinical Oncology · 被引 22)
• Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial (2025 · Journal of Clinical Oncology · 被引 12)
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial (2025 · Nature Communications · 被引 11)
• The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients (2024 · Breast Cancer Targets and Therapy · 被引 10)